Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: The UK perspective

PharmacoEconomics

Volumn 24, Issue 3, 2006, Pages 237-250

  Karnon, Jonathan ^a   Delea, Thomas ^b   Johnston, Stephen R D ^c   Smith, Robert ^d   Brandman, Jane ^e   Sung, Jennifer ^e   Goss, Paul E ^f  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b POLICY ANALYSIS INC PAI   (United States)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d South Carolina Oncology Associates   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

^f MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN RECEPTOR; LETROZOLE; PLACEBO; TAMOXIFEN;

ARTHRALGIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RECURRENCE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; HUMAN; NATIONAL HEALTH SERVICE; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; REVIEW; SENSITIVITY ANALYSIS; TERMINAL CARE;

AGED; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; FEMALE; HUMANS; MARKOV CHAINS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NITRILES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TRIAZOLES;

EID: 33644868306     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200624030-00004     Document Type: Review

References (25)

1. Harris JR, Morrow M, Bonadonna G. Cancer of the breast. In: De Vita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 4th ed. Philadelphia (PA): JB Lippencott Co., 1993
2. Glick JH. Adjuvant therapy for node-negative breast cancer. In: Fowble B, Goodman, RL, Glick JH, et al. Breast cancer treatment: a comprehensive guide to management. St Louis (MO): Mosby Year Book, 1991
3. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-67
4. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996; 14 (10): 2738-46
5. Goss P, Ingle J, Martino S, et al. A randomised trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. New Eng J Med 2003; 349 (19): 1793-802
6. Goss P, Ingle JN, Marino S, et al. Updated analysis of the NCIC CTG MA-17 randomized placebo controlled trial of letrozole after five years of tamoxifen in postmenopausal women with early stage breast cancer [abstract 847]. Proc Am Soc Clin Oncol; 2004 Jun 5-8; New Orleans
7. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13: 322-38
8. Karnon J, Brown J. Tamoxifen plus chemotherapy versus tamoxifen alone as adjuvant therapies for node positive postmenopausal women with early breast cancer. Pharmacoeconomics 2002; 20 (2): 119-37
9. Moran MS, Haffty BG. Local-regional breast cancer recurrence: prognostic groups based on patterns of failure. Breast J 2002; 8 (2): 81-7
10. Haylock BJ, Coppin CML, Jackson J, et al. Locoregional first recurrence after mastectomy: prospective cohort studies with and without immediate chemotherapy. Int J Radiat Oncol Biol Phys 2000; 46 (2): 355-62
11. Schmoor C, Sauerbrei W, Bastert G, et al. Role of isolated locoregional recurrence of breast cancer: results of four prospective studies. J Clin Oncol 2000; 18 (8): 1696-708
12. Kamby C, Sengelov L. Pattern of dissemination and survival following isolated locoregional recurrence of breast cancer. Breast Cancer Res Treat 1997; 45: 181-92
13. Borner M, Bacchi M, Goldhirsch A, et al. First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. J Clin Oncol 1994; 12: 2071-7
14. Toonkel LM, Fix I, Jacobsen LH, et al. The significance of local recurrence of carcinoma of the breast. Int J Radiat Oncol Biol Phys 1983; 9: 33-9
15. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19 (10): 2596-606
16. Department of Health. Financial matters. Appendix 1: health service cost index. 2004 May [online]. Available from URL: http://www.info.doh.gov.uk/doh/ finman.nsf [Accessed 2006 Feb 5]
17. British National Formulary. British Medical Association and the Royal Pharmaceutical Society of Great Britain, 2004 Mar [online]. Available from URL: http://www.bnf.org [Accessed 2006 Feb 5]
18. NHS Executive. The new NHS 2002 reference costs. London: Department of Health, 2002
19. Netten A, Curtis L. Unit costs of health and social care, PSSRU. Kent: University of Kent, 2003
20. Kanis JA, Brazier JE, Stevenson M, et al. Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 2002; 6 (29): 1-146
21. Sorensen S, Brown R, Benedict A, et al. Patient-rated utilities in postmenopausal early breast cancer: a cross country comparison. ISPOR Seventh Annual European Congress; 2004 Oct 24-26; Hamburg
22. Interim life tables for England and Wales 1999-2001. Actuary's Department. UK Government [online]. Available from URL: http://www.gad.gov.uk/ Life_Tables/Historical_Interim_life_tables.htm [Accessed 2006 Feb 5]
23. Gabriel SE, Kneeland TS, Melton LJ, et al. Health-related quality of life in economic evaluations for osteoporosis: whose values should we use? Med Dec Making 1999; 19: 141-8
24. National Institute for Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2004 Apr
25. Towse A, Pritchard C, Devlin N. Cost effectiveness thresholds: economic and ethical issues, 2002 [online]. Available from URL: http://www.ohe.org [Accessed 2006 Feb 10]